Table 4 The adjusted hazard ratio for OS and BCSS associated with NAC and AC in patients with different ages and cancer stages.

From: Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer

Characteristics

OS

 

BCSS

AHR

P value

AHR

P value

Age

 < 50

1.747 (1.278–2.388)

< 0.001

 

1.903 (1.371–2.642)

< 0.001

 ≥ 50

1.296 (1.021–1.647)

0.033

 

1.325 (1.010–1.739)

0.042

T stage

T1a

5.668 (4.706–92.413)

< 0.001

 

4.178 (3.098–76.211)

< 0.001

T1b

2.319 (1.403–3.835)

0.001

 

2.437 (1.392–4.266)

0.002

T1c

1.256 (1.019–1.549)

0.033

 

1.344 (1.068–1.691)

0.012

N stage

N0

1.285 (0.943–1.752)

0.112

 

1.344 (0,944–1.913)

0.101

N1

1.535 (1.135–2.075)

0.005

 

1.558 (1.115–2.175)

0.009

N2–N3

1.597 (1.068–2.389)

0.023

 

1.817 (1.203–2.744)

0.005

  1. AC adjuvant chemotherapy, NAC neoadjuvant chemotherapy, AHR adjusted hazard ratio.
Back to article page